Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-31

Clinical Trial Update: Gilenya in Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

This document reports the completion and results posting of a Phase 2 trial of fingolimod (Gilenya) in amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2015-12-31